Cancer-Killing New Drug Candidate Utilizing AI to Enhance FDA Investigational New Drug Research

GAINESVILLE, Fla.--(BUSINESS WIRE)--U.S. Precision Medicine, Inc. (USPM), a biopharma company developing novel cancer therapeutics, today announced it will use state-of-the-art artificial intelligence (AI) technology to bolster independent research that has proven the company’s small molecule candidate is highly effective in killing breast cancer. U.S. Precision Medicine’s new cancer drug candidate has demonstrated the ability to reduce tumor weight and volume by 85% in just 30 days of treatmen